• December 9, 2023

  Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

• November 30, 2023

  EISAI’S SALES SUBSIDIARY COLLABORATES WITH MINISTRY OF PUBLIC HEALTH (MOPH) IN THAILAND

• November 22, 2023

  EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 77TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING

• November 20, 2023

  LEQEMBI® Wins Best New Drug And Clinical Advance Of The Year at The Scrip Awards 2023

• November 16, 2023

  EISAI NAMED AS “GREATEST IR IMPROVEMENT PREMIUM COMPANY” AND “BEST CONTINUAL IR EFFORTS PREMIUM COMPANY” AT THE JAPAN INVESTOR RELATIONS ASSOCIATION 30TH ANNIVERSARY COMMEMORATIVE AWARDS

View All

• December 4, 2023

  Sustainability "Scientists Discuss the Development of a New Treatment for the Elimination of Mycetoma"

• November 8, 2023

  IR “Second Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2024 [Material, Webcast]”

• November 7, 2023

  IR “Second Quarter Financial Report for the Fiscal Year Ending March 31, 2024”

• November 6, 2023

  Sustainability "Lymphatic Filariasis Elimination Activities in Myanmar ー Message from a DEC Manager"

• October 27, 2023

  Sustainability "Eisai Participated in “RECYCLE TO END POLIO”, a Campaign Aiming for a Polio-Free World by Recycling PET Bottle Caps"

View All

• October 13, 2023

  Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications
  Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness

• March 9, 2023

  Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties

• February 17, 2023

  EISAI SUPPORTS RELIEF EFFORTS FOR EARTHQUAKE IN TURKEY AND SYRIA

• July 15, 2022

  Notification Regarding U.S. Research and Development Subsidiary

• April 1, 2022

  Humanitarian Support to Ukraine

View All